BYON4228 not checked

Byondis B.V.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
2 active
2 in total · 2 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“BYON4228 is a humanized monoclonal antibody (mAb) directed against SIRPα. BYON4228 IV infusion every four weeks until disease progression or unacceptable toxicity. Different doses. Rituximab IV infusion (375 mg/m2) starting from the second treatment cycle onwards. Weekly infusion during the first cycle and every four weeks in subsequent 5 cycles.”In the company’s words, NCT05737628 on ClinicalTrials.gov
Tested for
Lymphoma, Solid Tumor
Main trialPhase 1
“This is the first-in-human study with BYON4228, a humanized monoclonal antibody (mAb) directed against SIRPα.”In the company’s words, NCT05737628 on ClinicalTrials.gov
Other names
Truxima

Other drugs for Lymphoma

All 308 drugs for Lymphoma

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting Feb 2026 First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228
Phase 1Active, not recruiting Apr 2026 A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow BYON4228

Following is part of Solo: you see every change to BYON4228 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in